![](https://endpts.com/wp-content/uploads/2021/10/Behzad-Aghazadeh-Avoro-tile-scaled.jpg)
Behzad Aghazadeh, Avoro Capital managing partner
Avoro Capital, the deal killer behind the Seagen-Immunomedics blowup, has turned its eyes on Merck's Acceleron buyout
Merck’s proposed buyout of Acceleron Pharma represents a major bolt-on opportunity as the drugmaker looks to a future without megablockbuster Keytruda driving sales. But …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.